Pre-Open Stock Movers 03/26: (CNAT) (RHT) (FIVE) Higher; (SNDK) (SCMP) (WGO) Lower (more...) - InvestingChannel

Pre-Open Stock Movers 03/26: (CNAT) (RHT) (FIVE) Higher; (SNDK) (SCMP) (WGO) Lower (more…)

Conatus Pharmaceuticals (NASDAQ: CNAT) 47% HIGHER; announced top-line results from the company’s Phase 2 double-blind, placebo-controlled clinical trial of emricasan, a first-in-class, orally active pan-caspase protease inhibitor, in 38 patients with nonalcoholic fatty liver disease (NAFLD), including the subset of NAFLD patients with nonalcoholic steatohepatitis (NASH). The trial met its primary endpoint, showing a statistically significant (p

Related posts

Carl Icahn Increases His Stake In Take-Two Interactive To 10.68%

ValueWalk

iPad Mini Display Outperformed By Kindle Fire HD & Nexus 7

ValueWalk

Foxconn Might Open Manufacturing Plants In The U.S. [REPORT]

ValueWalk

Peter Cundill Protégé Tim McElvaine on Investing in Japan [VIDEO]

ValueWalk

Set Bing Home Page Image As Lock Screen In Windows 8

ValueWalk

Morning Market News: JCP, APO, MCHP, ZIP, ENR, LGF, EA, ATVI, COV, LNT

ValueWalk